Seven Fleet Capital Management LP Makes New $897,000 Investment in Silence Therapeutics PLC Sponsored ADR $SLN

Seven Fleet Capital Management LP bought a new stake in shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 147,600 shares of the company’s stock, valued at approximately $897,000. Silence Therapeutics accounts for about 0.7% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 27th largest position. Seven Fleet Capital Management LP owned 0.31% of Silence Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Nantahala Capital Management LLC boosted its stake in shares of Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock valued at $9,378,000 after purchasing an additional 500,000 shares in the last quarter. Millennium Management LLC raised its stake in Silence Therapeutics by 121.0% in the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after buying an additional 361,080 shares in the last quarter. Ishara Investments LP purchased a new stake in Silence Therapeutics during the fourth quarter worth $1,459,000. Opaleye Management Inc. purchased a new stake in Silence Therapeutics during the fourth quarter worth $480,000. Finally, UBS Group AG lifted its holdings in Silence Therapeutics by 34.5% during the third quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after buying an additional 78,854 shares during the period. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Up 2.5%

NASDAQ:SLN opened at $6.93 on Friday. Silence Therapeutics PLC Sponsored ADR has a 52 week low of $4.19 and a 52 week high of $8.40. The firm has a 50 day moving average of $6.79 and a 200 day moving average of $6.10. The stock has a market capitalization of $327.37 million, a price-to-earnings ratio of -4.36 and a beta of 1.48.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The firm had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. As a group, analysts expect that Silence Therapeutics PLC Sponsored ADR will post -0.95 EPS for the current year.

Wall Street Analysts Forecast Growth

SLN has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Finally, Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.